Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 19,643 shares, a drop of 47.3% from the August 15th total of 37,252 shares. Based on an average trading volume of 55,975 shares, the short-interest ratio is presently 0.4 days. Currently, 2.3% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Galmed Pharmaceuticals Stock Down 0.9%

Shares of GLMD stock traded down $0.04 during trading hours on Wednesday, hitting $4.59. 302,067 shares of the company’s stock were exchanged, compared to its average volume of 52,894. Galmed Pharmaceuticals has a fifty-two week low of $3.29 and a fifty-two week high of $13.20. The firm has a market cap of $4.78 million, a P/E ratio of -0.30 and a beta of 0.67. The firm has a 50 day moving average of $4.36 and a two-hundred day moving average of $4.71.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings results on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.12) by $0.26.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.